Published on 25/12/2025
How to Leverage FDA’s Product-Specific Guidances for ANDA Development
Introduction to Product-Specific Guidances (PSGs)
Product-Specific Guidances (PSGs) are FDA-issued documents that provide detailed recommendations on the design of bioequivalence (BE) studies and other development considerations for individual drug products. They are essential tools for generic drug manufacturers planning to submit an Abbreviated New Drug Application (ANDA).
By following PSGs, applicants can significantly reduce the risk of deficiencies during FDA review. These guidances help streamline BE study design, identify regulatory expectations early, and increase the probability of a successful first-cycle ANDA approval.
Where to Find PSGs: Accessing the FDA Database
PSGs are publicly available on the FDA Product-Specific Guidances database. Applicants can search by:
- Active ingredient
- Dosage form
- Route of administration
- Approval date
The PSG entry typically includes:
- Recommended BE study types (fasting, fed, single-dose, multiple-dose)
- Comparator product (RLD)
- Waiver recommendations (e.g., biowaivers for strengths)
- Specific guidance for
Why PSGs Are Critical in ANDA Development
FDA reviewers use PSGs as a benchmark when assessing the adequacy of ANDA submissions. Failure to adhere to PSG recommendations without a strong scientific justification may lead to:
- Complete Response Letters (CRLs)
- Delays in review timelines
- Additional clinical studies or data requests
Aligning your BE study protocol with the PSG not only increases the likelihood of approval but also helps avoid costly and time-consuming deficiencies.
Application in BE Study Design, Complex Generics, and Labeling Considerations
Applying PSGs in Bioequivalence Study Design
PSGs often dictate whether fasting and/or fed studies are needed, which dosage strength to test, and the preferred BE study type. For example:
- Escitalopram Oxalate Tablets: PSG recommends single-dose fasting BE study using 20 mg strength
- Metformin ER: PSG requires both fasting and fed BE studies with replicate crossover design
A sample BE study design based on PSG:
| Parameter | Study Recommendation |
|---|---|
| Study Type | Randomized, single-dose, 2-way crossover |
| Condition | Fasting |
| Subjects | Healthy adults (n=24) |
| Washout | 7 days |
| PK Endpoints | Cmax, AUC0–t, AUC0–∞ |
Role of PSGs in Complex Generics
PSGs are particularly valuable for complex generics, where demonstrating BE can be challenging due to the nature of the product (e.g., liposomes, transdermals, ophthalmics, or inhaled drugs).
For example, the PSG for Budesonide Inhalation Suspension outlines in vitro testing parameters and requirements for device similarity, particle size distribution, and aerodynamic performance—crucial aspects often overlooked in standard BE designs.
Impact of PSGs on Waiver Requests
PSGs may support requests for biowaivers for additional strengths, provided that:
- The product is qualitatively (Q1) and quantitatively (Q2) the same
- Dissolution profiles are similar (f2 > 50)
- BE has been demonstrated for the highest strength
Example: For Metoprolol Tartrate tablets, BE is recommended only for 100 mg, and lower strengths may be waived using dissolution testing.
Labeling Considerations in PSG-Driven Submissions
While PSGs do not directly dictate labeling, they help avoid pitfalls that lead to CRLs. For instance, if PSG recommends a particular reference standard or study arm, failing to reflect that in the labeling submission may result in rejection.
Best practice: Cross-reference PSG elements with RLD labeling during Module 1.14.1 submission to ensure consistency and compliance.
Regulatory Expectations and Review Strategy
FDA expects PSG compliance unless scientifically justified deviations are clearly explained in the ANDA and supported by literature or bridging studies.
If deviating from PSG, the pre-ANDA meeting is an essential forum to discuss BE protocols, formulation differences, or waiver rationales.
Real-World Example: Generic Lurasidone Hydrochloride
A sponsor used the PSG for Lurasidone HCl tablets, which required a fasting BE study using 160 mg strength. By aligning fully with PSG and using validated LC-MS/MS methods, the sponsor obtained first-cycle approval in under 10 months.
This avoided the need for additional bridging studies or clarification rounds, demonstrating the operational advantage of PSG compliance.
Conclusion: PSGs as Strategic Regulatory Tools
Product-Specific Guidances are more than just recommendations—they are FDA’s roadmap to regulatory success. Sponsors who utilize PSGs during:
- Formulation design
- BE study planning
- Labeling preparation
- Waiver submissions
are better positioned for faster ANDA approvals with fewer regulatory setbacks. In a GDUFA-driven environment where time equals money, leveraging PSGs is not just smart—it’s essential.